Display options
Cite
Zhang L, Cao LL, Yang DD, et al. Establishment and evaluation of a novel mouse model of peri/postmenopausal depression. Heliyon. 2019;5(2):e01195doi: 10.1016/j.heliyon.2019.e01195.
Zhang, L., Cao, L. L., Yang, D. D., Ding, J. H., Guo, X. D., Xue, T. F., Zhao, X. J., & Sun, X. L. (2019). Establishment and evaluation of a novel mouse model of peri/postmenopausal depression. Heliyon, 5(2), e01195. https://doi.org/10.1016/j.heliyon.2019.e01195
Zhang, Ling, et al. "Establishment and evaluation of a novel mouse model of peri/postmenopausal depression." Heliyon vol. 5,2 (2019): e01195. doi: https://doi.org/10.1016/j.heliyon.2019.e01195
Zhang L, Cao LL, Yang DD, Ding JH, Guo XD, Xue TF, Zhao XJ, Sun XL. Establishment and evaluation of a novel mouse model of peri/postmenopausal depression. Heliyon. 2019 Feb 04;5(2):e01195. doi: 10.1016/j.heliyon.2019.e01195. eCollection 2019 Feb. PMID: 30839939; PMCID: PMC6365542.
Copy Download .nbib Format: NLM
Share it on

Heliyon. 2019 Feb 04;5(2):e01195. doi: 10.1016/j.heliyon.2019.e01195. eCollection 2019 Feb.

Establishment and evaluation of a novel mouse model of peri/postmenopausal depression.

Heliyon

Ling Zhang, Lu-Lu Cao, Dan-Dan Yang, Jian-Hua Ding, Xu-Dong Guo, Teng-Fei Xue, Xiao-Jie Zhao, Xiu-Lan Sun

Affiliations

  1. Neuroprotective Drug Discovery Key Laboratory of Nanjing Medical University, Nanjing, Jiangsu, 211166, China.
  2. Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu, 211166, China.

PMID: 30839939 PMCID: PMC6365542 DOI: 10.1016/j.heliyon.2019.e01195

Abstract

Women are believed to be more vulnerable to develop depressive symptoms during the perimenopause compared to postmenopause. The traditional bilateral ovariectomy and chronic mild stress (CMS) stimulation animal model produces a postmenopausal depressive-like state but the transition from perimenopausal period to postmenopausal period was ignored. Thus we establish a novel animal model in which the mice were stimulated by CMS for three months and removed the ovaries by two-step operation, and then evaluate whether this novel model could be much better for preclinical study used as a peri/postmenopause depressive model. The present study systemically evaluated the changes induced by two-step ovariectomy plus CMS in the mice. The depression-like behaviors, the levels of corticosterone, estrogen, pro-inflammatory factors, neurotransmitters, as well as brain-derived neurotrophic factor were determined; the changes of estrogen receptors, serotonin receptors, uterine weight and bone microarchitecture were also observed. The results show that the behaviors and biochemical indexes of mice changed gradually over time. Our study suggests that this two-step ovariectomy operation plus CMS successfully establishes a more reasonable peri/postmenopausal depression animal model which effectively simulates the clinical symptoms of peri/postmenopausal depressive women.

Keywords: Endocrinology; Neuroscience

References

  1. Pharmacol Res. 2000 Mar;41(3):341-6 - PubMed
  2. Cell Tissue Res. 2000 May;300(2):231-7 - PubMed
  3. J Bone Miner Res. 2000 Oct;15(10):1965-73 - PubMed
  4. Endocrinology. 2001 Jun;142(6):2238-43 - PubMed
  5. Brain Res. 2001 Dec 20;922(2):201-8 - PubMed
  6. Biol Psychiatry. 2003 Jul 1;54(1):59-69 - PubMed
  7. Pharmacol Biochem Behav. 2004 Jul;78(3):523-9 - PubMed
  8. Neuropsychopharmacology. 2005 Sep;30(9):1598-609 - PubMed
  9. Mol Cell Endocrinol. 2008 Aug 13;290(1-2):31-43 - PubMed
  10. Osteoporos Int. 2009 Aug;20(8):1309-20 - PubMed
  11. Biochim Biophys Acta. 2010 Oct;1800(10):1136-44 - PubMed
  12. Expert Rev Respir Med. 2010 Aug;4(4):509-18 - PubMed
  13. Brain Res. 2011 Mar 16;1379:176-87 - PubMed
  14. Neuroscience. 2011 Sep 15;191:139-47 - PubMed
  15. Behav Brain Res. 2012 Feb 1;227(1):100-8 - PubMed
  16. Behav Pharmacol. 2012 Feb;23(1):98-104 - PubMed
  17. Menopause. 2012 Apr;19(4):387-95 - PubMed
  18. J Neurosci. 2012 Jun 13;32(24):8116-26 - PubMed
  19. Int J Neuropsychopharmacol. 2013 Jun;16(5):1071-82 - PubMed
  20. Pharmacol Ther. 2013 Jan;137(1):119-31 - PubMed
  21. Neurobiol Learn Mem. 2013 Mar;101:19-25 - PubMed
  22. Curr Drug Targets. 2014 Apr;15(4):432-41 - PubMed
  23. Am J Psychiatry. 2015 Mar 1;172(3):227-36 - PubMed
  24. Neurosci Biobehav Rev. 2015 Apr;51:164-88 - PubMed
  25. Neurosci Lett. 2016 May 27;622:67-71 - PubMed
  26. Int J Neuropsychopharmacol. 2016 Sep 21;19(9):null - PubMed
  27. J Affect Disord. 2016 Dec;206:174-180 - PubMed
  28. Psychoneuroendocrinology. 2016 Dec;74:240-250 - PubMed
  29. Menopause. 2017 May;24(5):490-496 - PubMed
  30. Biomed Pharmacother. 2017 Feb;86:414-425 - PubMed
  31. Behav Brain Res. 2017 May 30;326:307-321 - PubMed
  32. Psychoneuroendocrinology. 2017 Aug;82:107-116 - PubMed
  33. Biochem Pharmacol. 2017 Oct 1;141:56-62 - PubMed
  34. Neurogastroenterol Motil. 2017 Jul;29(7):null - PubMed
  35. Front Pharmacol. 2017 May 31;8:324 - PubMed
  36. Behav Brain Res. 2017 Sep 29;335:8-18 - PubMed
  37. J Steroid Biochem Mol Biol. 2017 Nov;174:96-113 - PubMed
  38. J Psychopharmacol. 2017 Sep;31(9):1091-1120 - PubMed
  39. Psychoneuroendocrinology. 2018 Jan;87:93-107 - PubMed
  40. Oncotarget. 2017 Sep 19;8(48):84028-84038 - PubMed
  41. Bone. 2018 Mar;108:55-61 - PubMed
  42. Maturitas. 2018 Feb;108:7-12 - PubMed
  43. Pharmacol Rep. 2018 Feb;70(1):37-46 - PubMed
  44. Psychopharmacology (Berl). 1985;85(3):367-70 - PubMed
  45. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11110-4 - PubMed
  46. J Affect Disord. 1993 Oct-Nov;29(2-3):85-96 - PubMed
  47. Endocrinology. 1997 Nov;138(11):4613-21 - PubMed

Publication Types